Our top pick for
Cardiff Oncology Inc is a biotechnology business based in the US. Cardiff Oncology shares (CRDF) are listed on the NASDAQ and all prices are listed in US Dollars. Cardiff Oncology employs 11 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.24|
|52-week range||$4.88 - $25.50|
|50-day moving average||$6.89|
|200-day moving average||$7.33|
|Wall St. target price||$25.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.68|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-5.02%|
|1 month (2021-09-21)||-6.87%|
|3 months (2021-07-21)||6.67%|
|6 months (2021-04-21)||-26.15%|
|1 year (2020-10-21)||-48.09%|
|2 years (2019-10-21)||494.29%|
|3 years (2018-10-19)||467.27%|
|5 years (2016-10-21)||46.82%|
|Gross profit TTM||$-10,869,403|
|Return on assets TTM||-16.46%|
|Return on equity TTM||-28.21%|
|Market capitalisation||$253.1 million|
TTM: trailing 12 months
There are currently 2.7 million Cardiff Oncology shares held short by investors – that's known as Cardiff Oncology's "short interest". This figure is 3.4% up from 2.6 million last month.
There are a few different ways that this level of interest in shorting Cardiff Oncology shares can be evaluated.
Cardiff Oncology's "short interest ratio" (SIR) is the quantity of Cardiff Oncology shares currently shorted divided by the average quantity of Cardiff Oncology shares traded daily (recently around 1.8 million). Cardiff Oncology's SIR currently stands at 1.46. In other words for every 100,000 Cardiff Oncology shares traded daily on the market, roughly 1460 shares are currently held short.
However Cardiff Oncology's short interest can also be evaluated against the total number of Cardiff Oncology shares, or, against the total number of tradable Cardiff Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cardiff Oncology's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Cardiff Oncology shares in existence, roughly 70 shares are currently held short) or 0.0729% of the tradable shares (for every 100,000 tradable Cardiff Oncology shares, roughly 73 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cardiff Oncology.
Find out more about how you can short Cardiff Oncology stock.
We're not expecting Cardiff Oncology to pay a dividend over the next 12 months.
Cardiff Oncology's shares were split on a 1:6 basis on 19 February 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiff Oncology shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cardiff Oncology shares which in turn could have impacted Cardiff Oncology's share price.
Over the last 12 months, Cardiff Oncology's shares have ranged in value from as little as $4.88 up to $25.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiff Oncology's is 1.7513. This would suggest that Cardiff Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.